TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation and promotes B-cell lymphomagenesis.

Pilar M Dominguez
Hussein Ghamlouch
Wojciech Rosikiewicz, The Jackson Laboratory
Parveen Kumar, The Jackson Laboratory
Wendy Béguelin
Lorena Fontan
Martín A Rivas
Patrycja Pawlikowska
Marine Armand
Enguerran Mouly
Miguel Torres-Martin
Ashley S Doane
Maria Teresa Calvo Fernandez
Matt Durant
Veronique Della-Valle
Matt Teater
Luisa Cimmino
Nathalie Droin
Saber Tadros
Samaneh Motanagh
Alan H Shih
Mark A Rubin
Wayne Tam
Iannis Aifantis
Ross L Levine
Olivier Elemento
Giorgio Inghirami
Michael R Green
Maria E Figueroa
Olivier A Bernard
Said Aoufouchi
Sheng Li, The Jackson Laboratory
Rita Shaknovich
Ari M Melnick


TET2 somatic mutations occur in ~10% of DLBCLs but are of unknown significance. Herein we show that TET2 is required for the humoral immune response and is a DLBCL tumor suppressor. TET2 loss of function disrupts transit of B-cells through germinal centers (GC), causing GC hyperplasia, impaired class switch recombination, blockade of plasma cell differentiation and a pre-neoplastic phenotype. TET2 loss was linked to focal loss of enhancer hydroxymethylation and transcriptional repression of genes that mediate GC exit such as PRDM1. Notably, these enhancers and genes are also repressed in CREBBP-mutant DLBCLs. Accordingly, TET2 mutation in patients yields a CREBBP-mutant gene expression signature, CREBBP and TET2 mutations are generally mutually exclusive, and hydroxymethylation loss caused by TET2 deficiency impairs enhancer H3K27 acetylation. Hence TET2 plays a critical role in the GC reaction and its loss of function results in lymphomagenesis through failure to activate genes linked to GC exit signals.